
Cerus Co. (NASDAQ:CERS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Cerus in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the biotechnology company will post earnings per share of $0.00 for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $4.00 price target on the stock. The consensus estimate for Cerus' current full-year earnings is ($0.08) per share.
Cerus (NASDAQ:CERS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The business had revenue of $43.24 million during the quarter, compared to analyst estimates of $47.44 million.
Cerus Stock Performance
CERS stock traded down $0.05 during trading on Tuesday, hitting $1.32. 1,010,583 shares of the company traded hands, compared to its average volume of 1,307,816. The stock's 50-day simple moving average is $1.33 and its 200 day simple moving average is $1.55. Cerus has a 1 year low of $1.12 and a 1 year high of $2.54. The company has a market cap of $252.33 million, a PE ratio of -12.00 and a beta of 1.55. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.
Institutional Investors Weigh In On Cerus
A number of institutional investors have recently modified their holdings of the business. Rockport Wealth LLC purchased a new position in Cerus during the fourth quarter worth approximately $25,000. Merit Financial Group LLC acquired a new stake in Cerus in the 1st quarter valued at $25,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Cerus in the 4th quarter worth $25,000. Cibc World Markets Corp acquired a new position in Cerus during the fourth quarter worth $26,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cerus during the first quarter worth $32,000. 78.37% of the stock is currently owned by institutional investors and hedge funds.
Cerus Company Profile
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Articles
Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.